NCT01372956已完成不适用
Cholesterol Goal Attainment Rate and Its Associated Factors Among Dyslipidemic Patients on Lipid-lowering Drug Therapy in Korea (CRESCENDO)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 4,950
- 试验地点
- 1
- 主要终点
- Cholesterol goal attainment rate according to NCEP-ATP III guideline
研究概览
简要总结
This is a multi-centre, cross-sectional, chart review study to investigate cholesterol goal attainment rates defined by modified NCEP-ATP III guidelines and define its possible determinants among Korean dyslipidemic patients
详细描述
MC MD
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient who has a dyslipidemia with a lipid profile result within 3 months
- •Patient who has a dyslipidemia without change of lipid lowering drug dosage during 3 months after lipid profile test.
排除标准
- •Patient who involved in this study previously.
- •Patient who participated in other clinical study with study drug within 90 days.
结局指标
主要结局
Cholesterol goal attainment rate according to NCEP-ATP III guideline
时间窗: Once, at enrollment
次要结局
- Factors for cholesterol goal achievement: Age, Family history, smoking history, waist circumstance, etc.(Once, at enrollment)
- Cholesterol goal attainment rate related to CHD or disease history(Once, at enrollment)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Real-life EValuation Of High Dose RosUvastatin in High Risk Patients After TitraTIONHypercholesterolemiaNCT00526721AstraZeneca1,482
Unknown
不适用
Risc Optimisation- Acute cor5onary SyndromeIschemic Heart DiseaseAcute Coronary SyndromeNCT03619395Parc de Salut Mar150
已完成
3 期
Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)HypercholesterolemiaNCT02476006Sanofi998
已完成
不适用
C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS)Cardiovascular RiskNCT00921752AstraZeneca1,500
已完成
3 期
A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-CholesterolHyperlipidemiaNCT00136942Pfizer's Upjohn has merged with Mylan to form Viatris Inc.370